Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

As drugs like Ozempic and Mounjaro continue to skyrocket in usage, doctors are encountering more cases linking them to ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

Find out if it's safe to drink alcohol during your Ozempic treatment, whether alcohol raises the risk of any sides effects, ...

Commercials run by Hims & Hers advertise prescription injectable weight-loss drugs without disclosing safety and risk information.

The Janus Henderson Global Sustainable Equity Managed Account Portfolio returned -5.71% (gross) for Q4 2024. Click here to ...